| Abstrakt: |
Research from the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia, focuses on chronic lymphocytic leukemia (CLL) and the impact of venetoclax treatment. The study highlights the rapid activation of a BAFF/BCL-2 survival axis in CLL cells during venetoclax therapy, leading to insights on improving treatment responses. By analyzing the early changes induced by venetoclax, researchers aim to enhance long-term outcomes for patients with CLL. This research underscores the importance of understanding how CLL cells adapt to targeted therapies and the potential benefits of co-targeting cytokine signals for more effective treatment strategies. [Extracted from the article] |
